论文部分内容阅读
生物制剂改变了幼年特发性关节炎(JIA)的传统治疗模式,使JIA患儿的病情得到了明显改善。JIA是一种异质性疾病,对JIA采用生物制剂治疗要评估患儿的病情,应根据疾病的不同临床表现开始不同的治疗方案,同时要仔细平衡治疗的风险和益处。现主要介绍国内外生物制剂在JIA中的应用现状及2011年美国风湿病学会发布的第1个关于治疗JIA的循证建议。
Biologics have changed the traditional treatment of juvenile idiopathic arthritis (JIA) and have significantly improved the condition of children with JIA. JIA is a heterogeneous disease that treats JIA with a biologic agent. To assess a child’s condition, different treatment options should be based on the different clinical manifestations of the disease, with careful consideration of the risks and benefits of treatment. Now mainly introduces the domestic and foreign biological agents in JIA status quo and the 2011 American College of Rheumatology released the first evidence on the treatment of JIA recommendations.